RocRock Bio and Pu Heng Technology have jointly released the results of their strategic cooperation, showcasing a novel "DNA origami assembled spheroid" model for assessing the cytotoxicity and infiltration of CAR-M.

On December 4, 2023, Arsen Arakelyan, Director of the Armenian Institute of Molecular Biology, Lilit Nersisyan, Director of the Armenian Institute of Bioinformatics, and Professor Li Bingnan from Shandong University visited RocRock Bio in China. They focused on hereditary Mediterranean fever and other rare diseases, conducting international academic exchanges and discussing potential diagnostic and therapeutic solutions. This visit aimed to integrate global resources and strengthen Sino-Armenian cooperation in academia and medicine to address rare disease treatment challenges in Mediterranean countries.

RocRock Bio has recently published its latest research findings. The article, titled "Enhanced infection efficiency and cytotoxicity mediated by Vpx-containing...", highlights...

In a significant move to advance the treatment of autoimmune diseases, RocRock Bio, Nanjing Gulou Hospital, and the Cell Therapy Drug Research Institute of Jiangsu Industrial Technology Research Institute entered into a strategic clinical collaboration on September 21, 2023. This partnership aims to jointly explore and develop CAR-M targeted therapies for autoimmune diseases...

On June 8, RocRock Bio and Shandong Port Medical Health Management Group held a signing ceremony. This event aims to foster cross - disciplinary collaboration and knowledge exchange, leverage both parties' professional technologies and resources, and advance the development of CAR-M therapy for solid tumors...

Pulmonary fibrosis is a chronic and progressive interstitial lung disease that significantly impairs respiratory function. It can lead to acute respiratory decompensation, acute coronary syndrome, congestive heart failure...

RocRock Bio participated in the STINT-NSFC Network "Transcriptome Complexity in Human Disease" closed - door seminar, which took place at Engsholms Slott Castle in Sweden from May 10 to 12...

RocRock Bio's project on "CAR-M Therapy for Relapsed and Refractory Ovarian Cancer" has recently gained ethical approval from the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University, allowing it to proceed with clinical trials.